{"version":"1.0","type":"link","title":"Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study.","author_name":"Kim MJ 외","author_url":"https://prs-insight.online/author/Kim%20MJ","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/98123","thumbnail_width":1200,"thumbnail_height":630}